[go: up one dir, main page]

PL448505A1 - Composition with barrier and virucidal properties against coronaviruses, especially SARS-CoV-2, method of obtaining it and use - Google Patents

Composition with barrier and virucidal properties against coronaviruses, especially SARS-CoV-2, method of obtaining it and use

Info

Publication number
PL448505A1
PL448505A1 PL448505A PL44850524A PL448505A1 PL 448505 A1 PL448505 A1 PL 448505A1 PL 448505 A PL448505 A PL 448505A PL 44850524 A PL44850524 A PL 44850524A PL 448505 A1 PL448505 A1 PL 448505A1
Authority
PL
Poland
Prior art keywords
composition
cov
barrier
properties against
obtaining
Prior art date
Application number
PL448505A
Other languages
Polish (pl)
Inventor
Malwina Sosnowska-Ławnicka
Marta KUTWIN
Ewa Sawosz-Chwalibóg
Anna HOTOWY
Sławomir Jaworski
Mateusz WIERZBICKI
Marlena Zielińska-Górska
Barbara Strojny-Cieślak
Original Assignee
Szkoła Główna Gospodarstwa Wiejskiego w Warszawie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Szkoła Główna Gospodarstwa Wiejskiego w Warszawie filed Critical Szkoła Główna Gospodarstwa Wiejskiego w Warszawie
Priority to PL448505A priority Critical patent/PL448505A1/en
Publication of PL448505A1 publication Critical patent/PL448505A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S423/00—Chemistry of inorganic compounds
    • Y10S423/40—Fullerene composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja, sposób jej przygotowania oraz zastosowanie do zapobiegania zakażeniom koronawirusami, zwłaszcza SARS-CoV-2. Kompozycja w postaci wodnego koloidu zawiera w składzie 10% ektoinę oraz 0,1% hydroksyfuleren C60(OH)40 zmieszane w stosunku objętościowym 2:1. Preparat nanosi się na komórki nabłonka nosa narażone na kontakt z białkiem otoczki wirusa. Celem nanoszenia preparatu jest utworzenie stabilnej i przepuszczającej powietrze powłoki ochronnej, która wykazuje właściwości barierowe i pułapkowania w płaszczu wodnym i wirusobójcze wobec koronawirusów.The subject of the application is a composition, method of preparation, and use for preventing coronavirus infections, particularly SARS-CoV-2. The composition, in the form of an aqueous colloid, contains 10% ectoine and 0.1% hydroxyfullerene C60(OH)40 mixed in a 2:1 volume ratio. The formulation is applied to nasal epithelial cells exposed to viral envelope protein. The purpose of applying the formulation is to create a stable and air-permeable protective coating that exhibits barrier and water-jacketing properties and virucidal properties against coronaviruses.

PL448505A 2024-05-08 2024-05-08 Composition with barrier and virucidal properties against coronaviruses, especially SARS-CoV-2, method of obtaining it and use PL448505A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL448505A PL448505A1 (en) 2024-05-08 2024-05-08 Composition with barrier and virucidal properties against coronaviruses, especially SARS-CoV-2, method of obtaining it and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL448505A PL448505A1 (en) 2024-05-08 2024-05-08 Composition with barrier and virucidal properties against coronaviruses, especially SARS-CoV-2, method of obtaining it and use

Publications (1)

Publication Number Publication Date
PL448505A1 true PL448505A1 (en) 2025-11-12

Family

ID=97636123

Family Applications (1)

Application Number Title Priority Date Filing Date
PL448505A PL448505A1 (en) 2024-05-08 2024-05-08 Composition with barrier and virucidal properties against coronaviruses, especially SARS-CoV-2, method of obtaining it and use

Country Status (1)

Country Link
PL (1) PL448505A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3287131A1 (en) * 2011-09-09 2018-02-28 Bitop AG Therapeutic uses of ectoine
US20230226056A1 (en) * 2020-05-10 2023-07-20 Bitop Ag Compatible solutes for preventing or treating sars-cov-2 infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3287131A1 (en) * 2011-09-09 2018-02-28 Bitop AG Therapeutic uses of ectoine
US20230226056A1 (en) * 2020-05-10 2023-07-20 Bitop Ag Compatible solutes for preventing or treating sars-cov-2 infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU K, GUO F, MA Y, YU X, FU X, LI W, HAN W.: "Int J Mol Sci. 2023 Sep 23;24(19):14471.", FUNCTIONALIZED FULLERENE POTENTIALLY INHIBITS SARS-COV-2 INFECTION BY MODULATING SPIKE PROTEIN CONFORMATIONAL CHANGES, DOI: 10.3390/ijms241914471 *
PAGE TM, ET AL.: "Small. 2023 Apr;19(15):e2206154.", FUNCTIONALIZED FULLERENE FOR INHIBITION OF SARS-COV-2 VARIANTS., DOI: 10.1002/smll.202206154. *

Similar Documents

Publication Publication Date Title
ZA202304935B (en) An aerosol-forming substrate
GB2395902A (en) Spontaneous emulsions containing cyclosporine
GEP20064002B (en) Metered dose inhaler
BR0112725A (en) Antimicotic Nail Polish Composition
NO20051688L (en) Pharmaceutical compositions having a modified carrier
BR112023016989A2 (en) AEROSOL PRECURSOR FORMULATIONS
CN108294043A (en) One kind flying anti-special-purpose suspension agent
PL448505A1 (en) Composition with barrier and virucidal properties against coronaviruses, especially SARS-CoV-2, method of obtaining it and use
UA102847C2 (en) Pestiidal aqueous suspension composition and methods of reducing viscosity and foaming of said composition
PT1276377E (en) BIOCIDAL COMPOSITIONS WHICH UNDERSTAND A GASOUS GEL CONTAINING HYDROFOBIC SILICA
UY39679A (en) A TYPE OF HERBICIDE COMPOSITION, AND ITS FORMULATION AND APPLICATION
WO2007022022A3 (en) Volumizing agents
BRPI0700832B8 (en) topical anesthetic composition comprising suspension of polymeric nanocapsules of lidocaine and prilocaine
MX2023010487A (en) Pesticidal compositions.
CN107926941A (en) A kind of zinc oxide antibacterial mildew inhibitor and its preparation method and application
AR023136A1 (en) IMPROVED WATER COMPOSITIONS
PL431580A1 (en) Preparation for regeneration and moistening of nasal mucosa
BR112023003472A2 (en) AEROSOL GENERATING COMPOSITION, ARTICLE, AEROSOL DELIVERY SYSTEM AND ITS USE, PASTE, METHOD OF PRODUCTION OF AN AEROSOL GENERATING COMPOSITION, METHOD FOR GENERATING AN AEROSOL
AR030693A1 (en) A COMPOSITION OF AQUININE RESIN AMINO, USE OF THE COMPOSITION TO IMPREGN PAPER OR CARTON, AND A FINISHED BLADE OR EDGE THAT INCLUDES CARTON OR IMPREGATED PAPER.
BR112023003699A2 (en) AQUEOUS ANTIPERSPIRANT COMPOSITION, METHOD TO REDUCE SWEATING AND USE OF THE COMPOSITION
MX2021014591A (en) Composition for coating substrates.
GB700115A (en) Improvements in disinfectants and deodorizers
PL443565A1 (en) Method of obtaining a nanocomposite based on polysaccharide - chitosan, nanocomposite obtained by the method and use of the nanocomposite
PL440496A1 (en) Method for improving the flowability of sodium naproxen
UA154355U (en) METHOD OF OBTAINING VOLUME SUPERHYDROPHOBIC COATING